Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy was written by Landsburg, Daniel J.;Nasta, Sunita D.;Gerson, James N.;Svoboda, Jakub;Chong, Elise A.;Schuster, Stephen J.;Barta, Stefan K.;Robinson, Kyle W.;Hughes, Mitchell E.. And the article was included in Leukemia & Lymphoma in 2022.Formula: C16H21Cl2N3O2 The following contents are mentioned in the article:
Our study is also unique in reporting time-to clin. response. While clin. responses as defined in this anal. could only be achieved by patients who demonstrated defined clin. signs/symptoms at the start of PV-based therapy, the majority of those patients who achieved a clin. response and had a subsequent radiog. assessment also achieved a radiog. response, suggesting that clin. response, when detectable, may be an indicator of disease response in this patient population. In conclusion, patients with relapsed/refractory DLBCL/ HGBL treated at our center with PV, with or without concurrent rituximab and/or bendamustine, frequently achieved rapid and durable responses. These findings may inform clin. management as well as investigational study design for this patient population. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Formula: C16H21Cl2N3O2).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Many drugs contain an imidazole ring, such as certain antifungal drugs, the nitroimidazole series of antibiotics, and the sedative midazolam.Formula: C16H21Cl2N3O2
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem